glp-1 obesity drug news today september 29 2025 Nutritional priorities to support therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Medicine Association, and The Obesity Society - Alarming rise in weight loss

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are widely used in the treatment of metabolic disorders, including type 2 diabetes (T2D) and obesity

This much-needed programme will offer URGENT help to address the issues seen in general practice as a result of the national shortage of GLP-1 Receptor Agonists

Obviously, it is too early to be overly hopeful since it is still necessary to determine the long-term effects of these compounds and properly verify the potential cardiovascular benefits

Medical app, 4.8/5, 1M+ downloads

Furthermore, AMPK inhibitor compound C abolished the metformin-mediated upregulation of GLP-1R level and PKA phosphorylation